Allosteric Modulation of Hemoglobin for Tissue Oxygenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conditions associated with inadequate erythrocyte function, such as anemia and hypoxia, lead to oxygen insufficiency and various pathological conditions, for which existing treatments are inadequate in enhancing oxygen delivery to tissues effectively.
Innovation Solution
Administration of 2,3-biphosphoglycerate (2,3-BPG) or myo-inositol trispyrophosphate (myo-ITP) or their functional variants, either alone or in combination with other active pharmaceutical ingredients, to enhance oxygen delivery to tissues, either systemically or locally, through formulations like hydrogels or liposomes, for conditions including wounds, anemia, and hypoxia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional treatments are used for anemia and hypoxia, then existing therapeutic approaches are maintained, but oxygen delivery to tissues is insufficient
Solution Approach 1:
The patent changes the chemical parameters of hemoglobin by introducing 2,3-BPG and myo-ITP as allosteric effectors. These compounds modify the hemoglobin-oxygen binding curve, shifting it to the right to increase oxygen unloading at tissue sites, thereby improving oxygen delivery without requiring changes in erythrocyte numbers or hemoglobin concentration
Solution Approach 2:
The patent uses 2,3-BPG and myo-ITP as intermediary substances that mediate between hemoglobin and oxygen. These compounds bind to hemoglobin and facilitate oxygen release, acting as chemical messengers that enhance the efficiency of oxygen transport and delivery to tissues
2Quantity of substance
If erythrocyte numbers or hemoglobin concentration are increased, then oxygen transport capacity improves, but the complexity of treatment increases
Solution Approach 1:
The patent employs small-molecule chemical compounds (2,3-BPG and myo-ITP) that are simple, easily administrable substances. These compounds provide a rapid and reversible mechanism for enhancing oxygen delivery without the complexity of blood transfusions, erythropoietin therapy, or other complex hematologic interventions
Solution Approach 2:
Instead of changing the quantity of erythrocytes or hemoglobin, the patent changes the functional parameters of hemoglobin through allosteric modulation. This approach achieves improved oxygen transport capacity through chemical modification rather than increasing blood volume or cell count, simplifying the treatment approach
3Quantity of substance
If 2,3-BPG or myo-ITP are administered, then oxygen release from hemoglobin increases, but the mechanism of action becomes more complex
Solution Approach 1:
The patent introduces 2,3-BPG and myo-ITP as intermediary molecules that bind to hemoglobin and facilitate oxygen release. These compounds act as chemical mediators that interact with hemoglobin's allosteric sites, triggering conformational changes that promote oxygen unloading without requiring complex cellular mechanisms
Solution Approach 2:
The patent modifies the hemoglobin molecule's functional parameters through allosteric effectors. By changing the binding affinity and cooperativity of hemoglobin for oxygen, the system achieves enhanced oxygen release through straightforward chemical interactions rather than complex physiological pathways
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds increase oxygen release from hemoglobin, effectively treating conditions like anemia, hypoxia, and enhancing tissue oxygenation, thereby improving wound healing and physical performance by ensuring adequate oxygen delivery to tissues.
Implementation Method 1
2,3-biphosphoglycerate (2,3-BPG) or myo-inositol trispyrophosphate (myo-ITP) or a functional variant thereof... increase oxygen release from hemoglobin
Implementation Method 2
myo-inositol trispyrophosphate (myo-ITP) or a functional variant thereof... increase oxygen release from hemoglobin
Data Source
AI summary
The present invention includes methods and compositions to enhance, inter alia, wound repair by administration of 2,3-biphosphoglycerate, myo-inositol trispyrophosphate, or a functional variant thereof.